ARCHIVES

ASCO: Anastrozole Adds Treatment Option, But Tamoxifen Remains Standard

This article is from The Cancer Letter archive.

Vol. 28 No. 33 | September 13, 2002

Download PDF Visit The Full Archive

Related Articles

Release of Mayo Pathology Report Would Be Needed To Confirm Stage IIA Diagnosis.

October 24, 2008

NCI-Approved Clinical Trials

December 30, 2005

Cancer Panel To Form Committee On Breast Cancer

October 11, 1991

Q&A: Data that Killed CYP2D6 Testing Contradict Fundamental Law of Nature

May 18, 2012

In Brief: No Such Thing As Premature Data, Fisher Says- Only Immature Evaluation, Premature Application

June 20, 1980

FDA Approves Lapatinib For Advanced Breast Cancer

March 30, 2007